- Sweden
- /
- Medical Equipment
- /
- OM:BIOVIT
How Many Hemcheck Sweden AB (publ) (STO:HEMC) Shares Did Insiders Buy, In The Last Year?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention that insider sales have been known to precede tough periods for a business. So we'll take a look at whether insiders have been buying or selling shares in Hemcheck Sweden AB (publ) (STO:HEMC).
Do Insider Transactions Matter?
It's quite normal to see company insiders, such as board members, trading in company stock, from time to time. However, most countries require that the company discloses such transactions to the market.
We would never suggest that investors should base their decisions solely on what the directors of a company have been doing. But it is perfectly logical to keep tabs on what insiders are doing. As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Check out our latest analysis for Hemcheck Sweden
The Last 12 Months Of Insider Transactions At Hemcheck Sweden
Over the last year, we can see that the biggest insider purchase was by Director Hjalmar Didrikson for kr542k worth of shares, at about kr5.42 per share. That implies that an insider found the current price of kr5.52 per share to be enticing. Of course they may have changed their mind. But this suggests they are optimistic. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. The good news for Hemcheck Sweden share holders is that an insider was buying at near the current price. The only individual insider to buy over the last year was Hjalmar Didrikson.
Hjalmar Didrikson bought a total of 205.58k shares over the year at an average price of kr4.10. You can see the insider transactions (by individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
Insider Ownership
For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 9.0% of Hemcheck Sweden shares, worth about kr7.8m, according to our data. But they may have an indirect interest through a corporate structure that we haven't picked up on. We do generally prefer see higher levels of insider ownership.
So What Do The Hemcheck Sweden Insider Transactions Indicate?
The fact that there have been no Hemcheck Sweden insider transactions recently certainly doesn't bother us. However, our analysis of transactions over the last year is heartening. While we have no worries about the insider transactions, we'd be more comfortable if they owned more Hemcheck Sweden stock. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To help with this, we've discovered 6 warning signs (3 are concerning!) that you ought to be aware of before buying any shares in Hemcheck Sweden.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
About OM:BIOVIT
Bio Vitos Pharma
Operates as a medical technology company in Sweden and internationally.
Medium-low with mediocre balance sheet.
Market Insights
Community Narratives
